New treatments for atopic dermatitis

Williams, Hywel (2002) New treatments for atopic dermatitis. British Medical Journal, 324 . pp. 1533-1534.

[img]
Preview
PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
159Kb

Abstract

Atopic dermatitis now affects 15% to 20% of chil­ dren in developed countries, and prevalence in cities in developing countries undergoing rapid demographic changes is quickly following suit.1 Most cases of atopic dermatitis in a given community are mild, but children with moderate to severe disease can have continuous itching and associated loss of sleep. The social stigma of a visible skin disease can also be soul destroying for both patient and family. A few studies have suggested that some degree of prevention of the disease is possible,2 although these measures have not been taken up widely. In the absence of any treatment that is known to alter the clinical course of the disease, most treatment is aimed at reducing symp­ toms and signs. After a relative lull of almost 40 years, new drugs—tacrolimus and pimecrolimus—have appeared that offer different approaches to managing this miserable disease. Do they work? Are they safe? And how do they compare with existing treatments?

Item Type:Article
Schools/Departments:Faculty of Medicine and Health Sciences > School of Medical and Surgical Sciences > Medicine
ID Code:862
Deposited By:attreed, karen
Deposited On:20 Mar 2008 11:49
Last Modified:20 Mar 2008 11:49

Repository Staff Only: item control page